|Articles|May 1, 2020
- Pharmaceutical Executive-05-01-2020
- Volume 40
- Issue 5
Pharmaceutical Executive, May 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
Pharm Exec's Emerging Pharma Leaders 2020over 5 years ago
AI: Kickstarting the Race Against COVID-19over 5 years ago
Competition for Biotech CFOs is Heating Upover 5 years ago
Biopharma Sustainability Considered Essentialover 5 years ago
CFOs Outlook: Forging a Sustainable Futureover 5 years ago
Drive for COVID-19 Therapies Raises Patent and Pricing Issuesover 5 years ago
Biotech in the Age of COVID: The Pain and the Gainover 5 years ago
A New, Less Friendly Normal Looms for European Drugmakersover 5 years ago
How Prepared Were Doctors for the COVID Digital Upswing?over 5 years ago
Pharmaceutical Executive, May 2020 Issue (PDF)Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model
5
